Cargando…

Pexidartinib Long‐Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors

BACKGROUND: Pexidartinib is approved in the U.S. for tenosynovial giant cell tumors (TGCTs). Herein, we assessed the hepatic safety profile of pexidartinib across patients with TGCTs receiving pexidartinib. MATERIALS, AND METHODS: Hepatic adverse reactions (ARs) were assessed by type and magnitude o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lewis, James H., Gelderblom, Hans, van de Sande, Michiel, Stacchiotti, Silvia, Healey, John H., Tap, William D., Wagner, Andrew J., Pousa, Antonio Lopez, Druta, Mihaela, Lin, Chia‐Chi, Baba, Hideo A., Choi, Youngsook, Wang, Qiang, Shuster, Dale E., Bauer, Sebastian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Sarcomas
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100574/ https://www.ncbi.nlm.nih.gov/pubmed/33289960 http://dx.doi.org/10.1002/onco.13629

Ejemplares similares

Exposure–response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor
por: Yin, Ophelia, et al.
Publicado: (2021)

Long‐term outcomes of pexidartinib in tenosynovial giant cell tumors
por: Gelderblom, Hans, et al.
Publicado: (2020)

Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors
por: Yin, Ophelia, et al.
Publicado: (2020)

Tenosynovial Giant Cell Tumor Observational Platform Project (TOPP) Registry: A 2-Year Analysis of Patient-Reported Outcomes and Treatment Strategies
por: Palmerini, Emanuela, et al.
Publicado: (2023)

Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial
por: Van De Sande, Michiel, et al.
Publicado: (2021)

Pexidartinib in the Management of Advanced Tenosynovial Giant Cell Tumor: Focus on Patient Selection and Special Considerations
por: Vaynrub, Anna, et al.
Publicado: (2022)

A prospective real‐world study of the diffuse‐type tenosynovial giant cell tumor patient journey: A 2‐year observational analysis
por: Bernthal, Nicholas M., et al.
Publicado: (2022)

Complementary Effects of Surgery and Pexidartinib in the Management of Patients with Complex Diffuse-Tenosynovial Giant Cell Tumor
por: Bernthal, Nicholas M., et al.
Publicado: (2022)

Single‐Center Experience with Ifosfamide Monotherapy as Second‐Line Treatment of Recurrent/Metastatic Osteosarcoma
por: Verschoor, Arie Jan, et al.
Publicado: (2019)

Pexidartinib (TURALIO™): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor
por: Monestime, Shanada, et al.
Publicado: (2020)

Management of Soft Tissue Sarcomas in Extremities: Variation in Treatment Recommendations and Surveillance According to Specialty and Continent
por: Acem, Ibtissam, et al.
Publicado: (2021)

Management of Tenosynovial Giant Cell Tumor: A Neoplastic and Inflammatory Disease
por: Healey, John H., et al.
Publicado: (2020)

Giant Cell Tumor of Bone: Effect of Longer Dosing Intervals of Denosumab on Tumor Control and Bone-related Complications
por: Jiang, Cindy Y, et al.
Publicado: (2022)

Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study
por: Zalcberg, John R., et al.
Publicado: (2021)

Efficacy of Trabectedin in Patients with Advanced Translocation‐Related Sarcomas: Pooled Analysis of Two Phase II Studies
por: Takahashi, Mitsuru, et al.
Publicado: (2017)

Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID‐19 Pandemic
por: Martin‐Broto, Javier, et al.
Publicado: (2020)

Tenosynovial giant cell tumor: case report of a patient effectively treated with pexidartinib (PLX3397) and review of the literature
por: Giustini, Nicholas, et al.
Publicado: (2018)

The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study
por: Bernthal, Nicholas M., et al.
Publicado: (2021)

External validation and adaptation of a dynamic prediction model for patients with high‐grade extremity soft tissue sarcoma
por: Rueten‐Budde, Anja J., et al.
Publicado: (2020)

Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors
por: Gantzer, Justine, et al.
Publicado: (2022)

Unplanned Excision of Soft Tissue Sarcomas of the Extremities in a Low-to-Middle-Income Country
por: Wang, Edward H. M., et al.
Publicado: (2023)

Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma
por: Massoth, Lucas R., et al.
Publicado: (2021)

Limb Amputation after Multiple Treatments of Tenosynovial Giant Cell Tumour: Series of 4 Dutch Cases
por: Mastboom, Monique J. L., et al.
Publicado: (2017)

Early symptoms of bone and soft tissue sarcomas: could they be diagnosed earlier?
por: George, A, et al.
Publicado: (2012)

Feasibility and Efficacy of Microwave Ablation Combined with Iodine‐125 Seed Implantation in Local Control of Recurrent Retroperitoneal Liposarcomas: Initial Clinical Experience
por: Lu, Mingjian, et al.
Publicado: (2017)

Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor
por: Menegaz, Brian A., et al.
Publicado: (2017)

Saving the hand: Role of multimodality therapy for Ewing's sarcoma family tumor of the palm
por: Joseph, Sanjay A., et al.
Publicado: (2018)

Defining Tumor Rupture in Gastrointestinal Stromal Tumor
por: Nishida, Toshirou, et al.
Publicado: (2019)

MRI Radiomic Features Are Independently Associated With Overall Survival in Soft Tissue Sarcoma
por: Spraker, Matthew B., et al.
Publicado: (2019)

The Landmark Series: Systemic Therapy for Resectable Gastrointestinal Stromal Tumors
por: Keung, Emily Z., et al.
Publicado: (2020)

Role of Resection Following Focal Progression with Standard Doses of Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses
por: Cho, Hyungwoo, et al.
Publicado: (2019)

Primary Angiosarcoma—A Rare Cause of Right Ventricular Outflow Tract Obstruction: Case Report and Literature Review
por: Omair, Mohammad, et al.
Publicado: (2019)

Atrial Thrombus Mimicking Ewing's Sarcoma
por: Hon, Matthew, et al.
Publicado: (2019)

Neoadjuvant Chemoradiation Compared With Neoadjuvant Radiation Alone in the Management of High-Grade Soft Tissue Extremity Sarcomas
por: Hazell, Sarah Z., et al.
Publicado: (2019)

First-In-Human Phase 1 Study of a Nonwoven Fabric Bioabsorbable Spacer for Particle Therapy: Space-Making Particle Therapy (SMPT)
por: Sasaki, Ryohei, et al.
Publicado: (2019)

Functional Outcome Measurement in Patients with Lower-Extremity Soft Tissue Sarcoma: A Systematic Literature Review
por: Kask, Gilber, et al.
Publicado: (2019)

Integrating Anatomical, Molecular and Clinical Risk Factors in Gastrointestinal Stromal Tumor of the Stomach
por: Hølmebakk, Toto, et al.
Publicado: (2021)

Soft Tissue Sarcoma of Lower Extremity: Functional Outcome and Quality of Life
por: Kask, Gilber, et al.
Publicado: (2021)

Percutaneous Cementoplasty for the Pelvis in Bone Metastasis: 12-Year Experience
por: Park, Jong Woong, et al.
Publicado: (2021)

Late Local Recurrence and Metastasis in Soft Tissue Sarcoma of the Extremities and Trunk Wall: Better Outcome After Treatment of Late Events Compared with Early
por: von Konow, Arvid, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nlc23hp7b71fkctuor4sk4opgi